cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1640Research ArticleОБЗОРЫREVIEWSЛечение стабильной ишемической болезни сердца: фокус на β-адреноблокаторыStable coronary heart disease treatment: focus on beta-adrenoblockersМаколкинВ. И.MakolkinV. I.dvmak@mail.ruМосковская медицинская академия им. И.М.Сеченова, г. МоскваI.M. Sechenov Moscow Medical Academy. Moscow200820122008768993Copyright © Маколкин В.И., 20082008Маколкин В.И.Makolkin V.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1640

Stable angina treatment with a prolonged-action beta-adrenoblocker, metoprolol succinate, is discussed. Themedication is effective, metabolically neutral, well tolerated and could also be used in patients with comorbidities.

ишемическая болезнь сердцастабильная стенокардияβ-адреноблокаторыcoronary heart diseasestable anginabeta-adrenoblockersReferencesОганов Р.Г, Лепахин В.К. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование АТР – Angina Treatment Pattern). Кардиология 2003; 5: 9-15.Оганов Р.Г, Лепахин В.К. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование АТР – Angina Treatment Pattern). Кардиология 2003; 5: 9-15.Kannel WB, Kannel C, Puffenberger RS, Cuppeles LA. Heart rate and cardiovascular mortality; the Framingham Study. Am Heart J 1987; 113: 1489-94.Kannel WB, Kannel C, Puffenberger RS, Cuppeles LA. Heart rate and cardiovascular mortality; the Framingham Study. Am Heart J 1987; 113: 1489-94.Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 1999; 159: 585-92.Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med 1999; 159: 585-92.Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. Eur Heart J 2005; 26: 967-74.Шальнова С.А. Частота сердечных сокращений и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005; 10: 45-50.Шальнова С.А. Частота сердечных сокращений и смертность от сердечно-сосудистых заболеваний у российских мужчин и женщин. Результаты эпидемиологического исследования. Кардиология 2005; 10: 45-50.Беленков Ю.Н. Лечение ишемической болезни сердца, старые традиции и новые тенденции. Тер архив 2005; 9: 5-8.Беленков Ю.Н. Лечение ишемической болезни сердца, старые традиции и новые тенденции. Тер архив 2005; 9: 5-8.Фуфаев Е.Н. К вопросу о методике клиническо-социальных исследований по изучению потребности в кардиохирургической помощи. Качест клин прак 2003; 2: 108-13.Фуфаев Е.Н. К вопросу о методике клиническо-социальных исследований по изучению потребности в кардиохирургической помощи. Качест клин прак 2003; 2: 108-13.Отчет АНА по сердечно-сосудистым заболеваниям 2004; с. 10.Отчет АНА по сердечно-сосудистым заболеваниям 2004; с. 10.Haiat R, Leroy G. Cardiovascular therapeutics. Ed. Frison-Roche, Paris 1999; 346.Haiat R, Leroy G. Cardiovascular therapeutics. Ed. Frison-Roche, Paris 1999; 346.Кардиология (национальное руководство). Москва «Гэотар-Медиа» 2007; 1232.Кардиология (национальное руководство). Москва «Гэотар-Медиа» 2007; 1232.The MIAMI Trial Research Group.1985. Metoprolol in acute myocardial infartion (MIAMI).A randomized placebo controlled international trial. Eur Heart J 1985; 6: 199-226.The MIAMI Trial Research Group.1985. Metoprolol in acute myocardial infartion (MIAMI).A randomized placebo controlled international trial. Eur Heart J 1985; 6: 199-226.Norwegian Study Group. Timolol-indused reduction in Mortality and reinfarction in patients surviving acute myocardial infarction. New Engl J Med 1981; 304: 801-7.Norwegian Study Group. Timolol-indused reduction in Mortality and reinfarction in patients surviving acute myocardial infarction. New Engl J Med 1981; 304: 801-7.Frishman WN. Postinfarction survival: role of betaadrenic blockade, in Fuster V (ed): Atherosclerosis and Coronary Artery Disease. Philadelphia. Lippincott 1996; 1205-14.Frishman WN. Postinfarction survival: role of betaadrenic blockade, in Fuster V (ed): Atherosclerosis and Coronary Artery Disease. Philadelphia. Lippincott 1996; 1205-14.The BHAT research group. A randomized trial of propranolol in patients with acute myocardial infarction. I Mortality results. JAMA 1982; 247: 1707-14.The BHAT research group. A randomized trial of propranolol in patients with acute myocardial infarction. I Mortality results. JAMA 1982; 247: 1707-14.The BHAT research group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 1983; 250: 2814-9.The BHAT research group. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 1983; 250: 2814-9.Viscoli CM, HorwitzRI, Singer BH. Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Ann Intern Med 1993; 118: 99-105.Viscoli CM, HorwitzRI, Singer BH. Beta-blockers after myocardial infarction: influence of first-year clinical course on long-term effectiveness. Ann Intern Med 1993; 118: 99-105.Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis infarction (TIMI) II-B Study. Circulation 1991; 83: 422-37.Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred β-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis infarction (TIMI) II-B Study. Circulation 1991; 83: 422-37.The Beta-Blocker Pooling Project Research Group. Eur Heart J 1988; 9: 8-16.The Beta-Blocker Pooling Project Research Group. Eur Heart J 1988; 9: 8-16.Savonitto S, Ardissino D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) study. JACC 1996; 27: 311-6.Savonitto S, Ardissino D, Egstrup K, et al. Combination therapy with metoprolol and nifedipine versus monotherapy in patients with stable angina pectoris. Results of the International Multicenter Angina Exercise (IMAGE) study. JACC 1996; 27: 311-6.Effect of metoprolol on prognosis for patients with suspected acute myocardial infarction and indirect sings of congestive heart failure (A subgroup analysis of the Goteborg metoprolol trial). Am J Cardiol 1997; 80(B): 40J-4.Effect of metoprolol on prognosis for patients with suspected acute myocardial infarction and indirect sings of congestive heart failure (A subgroup analysis of the Goteborg metoprolol trial). Am J Cardiol 1997; 80(B): 40J-4.Houtzagers T, Olsson G, Barber HJ, et al. Efficacy and tolerability of a new controlled-release formulation of metoprolol: a comparison with conventional metoprolol tablets in mild to moderate hypertension. Eur J Clin Pharmacol 1988; 33(Suppl): 39-44.Houtzagers T, Olsson G, Barber HJ, et al. Efficacy and tolerability of a new controlled-release formulation of metoprolol: a comparison with conventional metoprolol tablets in mild to moderate hypertension. Eur J Clin Pharmacol 1988; 33(Suppl): 39-44.Egstrup K, Rasmussen K, Omland T, et al. The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily. J Clin Pharmacol 1988; 33: 45-9.Egstrup K, Rasmussen K, Omland T, et al. The antianginal efficacy and tolerability of controlled-release metoprolol once daily: a comparison with conventional metoprolol tablets twice daily. J Clin Pharmacol 1988; 33: 45-9.Kendall V, AkblagbiS, Hugbes B, et al. Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol? J Clin Pharmacol 1990; 30: 98-102.Kendall V, AkblagbiS, Hugbes B, et al. Is metoprolol CR/ZOK more selective than conventional metoprolol and atenolol? J Clin Pharmacol 1990; 30: 98-102.Kerr D, MacDonald IA, Heller SR et al. Beta-adrenoreceptor and hypoglycaemia. A randomized, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol 1990; 29(6): 685-93.Kerr D, MacDonald IA, Heller SR et al. Beta-adrenoreceptor and hypoglycaemia. A randomized, double-blind, placebo controlled comparison of metoprolol CR, atenolol and propranolol LA in normal subjects. Br J Clin Pharmacol 1990; 29(6): 685-93.Benfield P, Clissold SP, Brogden RN. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischemic heart disease and related cardiovascular disorders. Drugs 1986; 31(5): 376-429.Benfield P, Clissold SP, Brogden RN. Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischemic heart disease and related cardiovascular disorders. Drugs 1986; 31(5): 376-429.Wiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-7.Wiklund O, Hulthe J, Wikstrand J, et al. Effect of controlled release/extended release metoprolol on carotid intima-media thickness in patients with hypercholesterolemia: a 3-year randomized study. Stroke 2002; 33: 572-7.Hedblad B, Wikstrand J, Janzon L, et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-6.Hedblad B, Wikstrand J, Janzon L, et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: Main results from the Beta-Blocker Cholesterol-Lowering Asymptomatic Plaque Study (BCAPS). Circulation 2001; 103: 1721-6.Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation 2001; 104: 1477-82.Omvik P, LeerJ, Istad H, et al. Equal Efficacy and Improved Tolerability with 50 mg Controlled-Release Metoprolol Compared with 100 mq Conventional Metoprolol in Hypertensive Patients. Am J Ther 1994; 1: 65-73.Omvik P, LeerJ, Istad H, et al. Equal Efficacy and Improved Tolerability with 50 mg Controlled-Release Metoprolol Compared with 100 mq Conventional Metoprolol in Hypertensive Patients. Am J Ther 1994; 1: 65-73.Franzen D. Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study International. J Impotence Res 2001; 13: 348-51.Franzen D. Effects of beta-blockers on sexual performance in men with coronary heart disease. A prospective, randomized and double blinded study International. J Impotence Res 2001; 13: 348-51.Hjalmarson A, Goldstein S, Fagerberg B, et al. Effect of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized International Trials in Congestive heart failure (MERIT-HF). JAMA 2000; 283: 1295-302.Hjalmarson A, Goldstein S, Fagerberg B, et al. Effect of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure. The Metoprolol CR/XL Randomized International Trials in Congestive heart failure (MERIT-HF). JAMA 2000; 283: 1295-302.Овчаренко С.И., Литвинова И.В., Маколкин В.И. Применение β-адреноблокторов у больных с сердечно-сосудистой патологией в сочетании с хронической бронхообструкцией. Врач 2006; 12: 27-9.Овчаренко С.И., Литвинова И.В., Маколкин В.И. Применение β-адреноблокторов у больных с сердечно-сосудистой патологией в сочетании с хронической бронхообструкцией. Врач 2006; 12: 27-9.Овчаренко С.И., Литвинова И.В., Маколкин В.И. Использование кардиоселективного β-адреноблокатора метопролола сукцината у пациентов с сердечной сосудистой патологией и бронхообструктивным синдромом. Клин фармак тер 2006; 15(4): 1-4.Овчаренко С.И., Литвинова И.В., Маколкин В.И. Использование кардиоселективного β-адреноблокатора метопролола сукцината у пациентов с сердечной сосудистой патологией и бронхообструктивным синдромом. Клин фармак тер 2006; 15(4): 1-4.Von Armin. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBS) follow-up. JACC 1996; 28: 20-4.Von Armin. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBS) follow-up. JACC 1996; 28: 20-4.

The authors declare that there are no conflicts of interest present.